AR046901A1 - Composiciones farmaceuticas - Google Patents
Composiciones farmaceuticasInfo
- Publication number
- AR046901A1 AR046901A1 ARP040104696A ARP040104696A AR046901A1 AR 046901 A1 AR046901 A1 AR 046901A1 AR P040104696 A ARP040104696 A AR P040104696A AR P040104696 A ARP040104696 A AR P040104696A AR 046901 A1 AR046901 A1 AR 046901A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- compound represented
- chemical formula
- vehicle
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Composiciones novedosas útiles para el tratamiento de enfermedades dependientes de los andrógenos. Reivindicación 1: Una composición aceptable desde el punto de vista farmacéutico que comprende una cantidad efectiva del compuesto representado por la fórmula química estructural (1), la cual comprende: o una sal del mismo aceptable desde el punto de vista farmacéutico, mezclado con un vehículo hidrofílico seleccionado entre el grupo que consiste de sílica y celulosa microcristalina, donde dicho compuesto representado por la fórmula química estructural (1) está absorbido sobre dicho vehículo hidrofílico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53046603P | 2003-12-17 | 2003-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046901A1 true AR046901A1 (es) | 2005-12-28 |
Family
ID=34700140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104696A AR046901A1 (es) | 2003-12-17 | 2004-12-16 | Composiciones farmaceuticas |
Country Status (5)
Country | Link |
---|---|
US (2) | US20050153976A1 (es) |
AR (1) | AR046901A1 (es) |
PE (1) | PE20050759A1 (es) |
TW (1) | TW200528110A (es) |
WO (1) | WO2005058281A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7759339B2 (en) | 2005-03-31 | 2010-07-20 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
JP5840703B2 (ja) * | 2011-05-16 | 2016-01-06 | オムニアクティブ ヘルス テクノロジーズ リミテッド | 増強された生物学的利用能を有するクルクミンを含む水溶性組成物およびその製法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5598113A (en) * | 1979-01-17 | 1980-07-25 | Eisai Co Ltd | Medicinal powder having improved absorbability |
DE3409063A1 (de) * | 1984-03-13 | 1985-09-19 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von fliessfaehigen cholinchlorid-kieselsaeure-pulvern |
GB8413191D0 (en) * | 1984-05-23 | 1984-06-27 | Beecham Group Plc | Pharmaceutical composition |
US4721709A (en) * | 1984-07-26 | 1988-01-26 | Pyare Seth | Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions |
US6303167B1 (en) * | 1998-11-09 | 2001-10-16 | Archer-Daniels-Midland Company | Method of producing vitamin powders |
AR036492A1 (es) * | 2001-09-06 | 2004-09-15 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes |
JP4309761B2 (ja) * | 2001-10-17 | 2009-08-05 | シェーリング コーポレイション | アンドロゲン依存性疾患の治療を目的とする17βヒドロキシステロイドデヒドロゲナーゼ3型の阻害剤としてのピペリジンアセトアミンおよびピペラジンアセトアミン |
US20030206978A1 (en) * | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
CA2516096A1 (en) * | 2003-02-19 | 2004-09-02 | Lifecycle Pharma A/S | Use of a silica or silica derivative as a sorption material |
-
2004
- 2004-12-16 AR ARP040104696A patent/AR046901A1/es unknown
- 2004-12-16 TW TW093139178A patent/TW200528110A/zh unknown
- 2004-12-16 US US11/013,676 patent/US20050153976A1/en not_active Abandoned
- 2004-12-16 WO PCT/US2004/042135 patent/WO2005058281A1/en active Application Filing
-
2005
- 2005-01-03 PE PE2005000030A patent/PE20050759A1/es not_active Application Discontinuation
-
2008
- 2008-12-09 US US12/331,015 patent/US20090111831A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090111831A1 (en) | 2009-04-30 |
WO2005058281A1 (en) | 2005-06-30 |
TW200528110A (en) | 2005-09-01 |
PE20050759A1 (es) | 2005-10-26 |
US20050153976A1 (en) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60142891D1 (de) | Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung | |
BRPI0511504A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides | |
PA8591701A1 (es) | Derivados de pirrolopirimidina | |
CU20100200A7 (es) | Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias | |
BRPI0412659A (pt) | isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto | |
AR053412A1 (es) | Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos | |
AR040021A1 (es) | (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion | |
HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
BRPI0415121A (pt) | material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida | |
AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
HK1155146A1 (zh) | 作為藥物活性劑的茚衍生物 | |
AR039936A1 (es) | Formulacion farmaceutica de liberacion modificada | |
EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
ECSP088457A (es) | Compuestos de benzamida útiles como inhibidores de la histona deacetilasa | |
ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
AR039935A1 (es) | Formulacion farmaceutica de liberacion inmediata | |
DE60025503D1 (de) | Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten | |
UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
AR046901A1 (es) | Composiciones farmaceuticas | |
DE602004001969D1 (de) | Orale pharmazeutische Zusammensetzung und Verfahren zu ihrer Herstellung | |
SE0102057D0 (sv) | New Salts I | |
AR057403A1 (es) | 4- anilino-3-quinolincarbonitrilos para el tratamiento del cancer | |
AR033779A1 (es) | Compuestos utiles en la enfermedad de reflujo | |
RS20050776A (en) | A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment diabetes | |
SE0301371D0 (sv) | New Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |